BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
125.09
-4.87 (-3.75%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close129.96
Open129.13
Bid125.44 x 1100
Ask129.80 x 1100
Day's range124.02 - 132.85
52-week range87.49 - 236.17
Volume686,909
Avg. volume785,975
Market cap6.842B
Beta (3Y monthly)2.87
PE ratio (TTM)N/A
EPS (TTM)-10.48
Earnings date19 Feb 2019 - 25 Feb 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est180.94
Trade prices are not sourced from all markets
  • Here's Why CRISPR Therapeutics Stock Fell Today
    Motley Fool21 hours ago

    Here's Why CRISPR Therapeutics Stock Fell Today

    A Wall Street analyst isn't too optimistic about the company's lead candidate.

  • GlobeNewswire2 days ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. On December 1, 2018, bluebird bio disclosed to the market that the Company had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” An article posted on December 3, 2018, to Seeking Alpha commented on the announcement, asserting “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” Based on this news, shares of bluebird bio fell more than 5% on the same day.

  • Here's What Pushed bluebird bio Stock Down 44.3% in 2018
    Motley Fool11 days ago

    Here's What Pushed bluebird bio Stock Down 44.3% in 2018

    Disappointing drug launches for expensive, single-application treatments poured water on otherwise impressive progress.

  • 3 Biotech Stocks to Watch in 2019
    Motley Fool11 days ago

    3 Biotech Stocks to Watch in 2019

    Clinical-trial and regulatory-review decisions make these three drug developers worth keeping tabs on this year.

  • The Wall Street Journal15 days ago

    Biotech Proposes Paying for Pricey Drugs by Installment

    A Boston-area biotech says it may have a found a way to handle the expected seven-figure cost of its experimental gene therapy: paying on installment. Bluebird Bio Inc. is developing plans to sell its first gene-replacement therapy, for a rare inherited blood disease, on a five-year installment plan, with each annual payment contingent on its treatment’s continued effectiveness. “Whether it’s just below or considerably below [$2.1 million] is something we need to sort through,” Mr. Leschly said.

  • Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
    Zacks15 days ago

    Celgene (CELG) Provides Guidance for 2019, Updates Pipeline

    Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.

  • bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies
    Business Wire16 days ago

    bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies

    “Access to the Inhibrx sdAb binder technology will allow us to combine the advancements we’ve made with our T cell therapy platform with their sdAb binder technology to generate novel cellular therapies with the potential to help patients in their fight against cancer,” said Philip Gregory, D. Phil., chief scientific officer, bluebird bio. “We are pleased to have formalized our relationship with bluebird bio, allowing us to couple our proprietary sdAb platform with a leading cell therapy platform,” said Brendan Eckelman, Chief Scientific Officer and Executive Vice President of Corporate Strategy of Inhibrx.

  • Here's Why bluebird bio Shares Got Knocked Down 19.3% in December
    Motley Fool19 days ago

    Here's Why bluebird bio Shares Got Knocked Down 19.3% in December

    Data presented by a competitor increased the risk to its most promising clinical-stage therapy.

  • How Celgene Is Positioned Now
    Market Realist19 days ago

    How Celgene Is Positioned Now

    What to Expect from Bristol-Myers Squibb's Acquisition of Celgene (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Celgene’s (CELG) revenues grew ~18% YoY to reach $11.2 billion from $9.5 billion. Wall Street analysts anticipate that Celgene will report net revenues of $15.2 billion in fiscal 2018, which represents ~17.14% YoY growth. Celgene also provided net revenue guidance for fiscal 2018 to ~$15.2 billion. Celgene estimated that its top products Revlimid, Pomalyst, Otezla, and Abraxane will generate net revenues of $9.7 billion, $2.0 billion, $1.6 billion, and $1.0 billion, respectively, in fiscal 2018. ## Earnings trends In the first nine months of 2018, Celgene’s net income declined ~2% to reach $2.97 billion from $3.02 billion. However, in the third quarter, Celgene’s net income grew ~10% to reach $1.1 billion from $988.0 million. Wall Street analysts expect Celgene to generate a net income of $4.2 billion in fiscal 2018, which represents ~43.67% YoY growth. In the first nine months of 2018, Celgene’s diluted EPS grew ~8% to reach $4.02 from $3.72. Celgene provided EPS guidance for fiscal 2018 to be in the range of $5.25 and $5.75. Wall Street analysts estimate that Celgene is expected to report EPS of $5.73 in fiscal 2018, which represents ~57.42% YoY growth. ## Celgene’s portfolio update Celgene is conducting a phase 1/2 EVOLVE trial of JCARH125, which is evaluating the safety and efficacy of the drugs in the treatment of patients with relapsed or refractory multiple myeloma (or RRMM). Celgene in collaboration with bluebird bio (BLUE) is also conducting a phase 1 trial of bb21217 to evaluate the safety and efficacy of the drug in the treatment of RRMM. In the third quarter of 2018, Celgene initiated the phase 3 COMMANDS trial for evaluation of the safety and efficacy parameters of luspatercept in MDS (myelodysplastic syndromes) patients who are erythropoiesis-stimulating agent-naïve, very low, low or at intermediate risk. Continue to Next Part Browse this series on Market Realist: * Part 1 - Bristol-Myers Squibb to Acquire Celgene * Part 3 - How Bristol-Myers Squibb Stands Now * Part 4 - What to Expect from BMY’s Celgene Acquisition

  • Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
    Zacks19 days ago

    Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus

    The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.

  • GlobeNewswire20 days ago

    ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. On December 1, 2018, bluebird bio disclosed to the market that the Company had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” An article posted on December 3, 2018, to Seeking Alpha commented on the announcement, asserting “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” Based on this news, shares of bluebird bio fell more than 5% on the same day.

  • Business Wire20 days ago

    bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference

    bluebird bio, Inc. (BLUE) today announced that members of the management team will present at the 37th Annual J.P. Morgan Healthcare Conference, Tuesday, January 8, at 2:30 p.m. PT at the Westin St. Francis Hotel, San Francisco, followed by a question and answer breakout session at 3:00 p.m. To access the live webcast of bluebird bio’s presentation and breakout session, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conference.

  • How Are Sangamo Therapeutics’ Earnings and Expenses Trending?
    Market Realist21 days ago

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    Who Is Eyeing Sangamo Therapeutics Now?(Continued from Prior Part)Earnings trends In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

  • A Financial Overview of Sangamo Therapeutics in December 2018
    Market Realist21 days ago

    A Financial Overview of Sangamo Therapeutics in December 2018

    Who Is Eyeing Sangamo Therapeutics Now?(Continued from Prior Part)Revenue trends In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.

  • How Analysts View Sangamo Therapeutics in December
    Market Realist21 days ago

    How Analysts View Sangamo Therapeutics in December

    Who Is Eyeing Sangamo Therapeutics Now?Stock performance On December 27, Sangamo Therapeutics (SGMO) stock price closed at $10.59, which is a ~1.58% decline from its prior day close of $10.76 on December 26, 2018.

  • Do Analysts See Any Upside in BeiGene Stock?
    Market Realist26 days ago

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.” 

  • Understanding BeiGene’s Operational Performance
    Market Realist26 days ago

    Understanding BeiGene’s Operational Performance

    In its most recent quarter, BeiGene’s (BGNE) selling, general, and administrative expenses rose YoY (year-over-year) to $48.82 million from $15.64 million primarily due to an increased head count.

  • Assessing BeiGene Limited’s Gross Margin Trend
    Market Realist26 days ago

    Assessing BeiGene Limited’s Gross Margin Trend

    In the third quarter, BeiGene’s (BGNE) total revenue fell YoY (year-over-year) to $54.2 million from $220.21 million. During the quarter, it generated $10.24 million from the US market and $43.96 million from outside the United States. During the comparable period in 2017, it generated $137.4 million from the US market and $82.81 million from outside the United States.

  • Taking Stock of BeiGene’s Latest Performance
    Market Realist26 days ago

    Taking Stock of BeiGene’s Latest Performance

    BeiGene Limited (BGNE) is a biopharmaceutical company with a focus on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer. In this series, we’ll explore BeiGene’s financials, valuation, and analyst views.

  • GlobeNewswire27 days ago

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. On December 1, 2018, bluebird bio disclosed to the market that the Company had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” An article posted on December 3, 2018, to Seeking Alpha commented on the announcement, asserting “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” Based on this news, shares of bluebird bio fell more than 5% on the same day.

  • Business Wire28 days ago

    INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Business Wirelast month

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • Business Wirelast month

    EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against bluebird bio, Inc. – BLUE

    Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of bluebird bio, Inc. resulting from allegations that bluebird bio may have issued materially misleading business information to the investing public.

  • Do Analysts See Any Upside for bluebird bio Stock?
    Market Realistlast month

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million compared to its net interest expense of $1.15 million in the previous year’s period. The company’s net income fell YoY (year-over-year) to -$145.48 million from -$78.8 million, translating to a net income per share of -$2.73. Of the 23 analysts covering bluebird bio stock, 16 have given it “buy” or higher ratings, and seven have given it “holds.” Analysts’ mean rating for bluebird stock is 1.96, and their target price is $184.94, implying a potential 79.9% upside for the stock based on its December 18 price of $102.79.

  • Understanding bluebird bio’s Operational Performance
    Market Realistlast month

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively, compared to its revenue of $35.43 million in 2017. Meanwhile, peers Amgen (AMGN), Sarepta Therapeutics (SRPT), and Vertex Pharmaceuticals (VRTX) are expected to generate revenues of $23.36 billion, $301.13 million, and $2.99 billion, respectively, in 2018.